8-K 1 insom8k.txt FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2001 Neurocrine Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 0-28150 33-0525145 (State or Other (Commission File Number) (I.R.S. Employer Jurisdiction of Incorporation) Identification No.) 10555 Science Center Drive, San Diego, California 92121 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (858) 658-7600 This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the "Company"), in connection with the matters described herein. Item 5. Other Events. On November 16, 2001, the Company announced that it has initiated the first pivotal Phase III clinical trial of NBI-34060 in approximately 500 patients with chronic (primary) insomnia. A copy of the Company's press release announcing the initiation of the clinical trial, dated November 16, 2001, is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7. Exhibits. (c) Exhibits. Exhibit Number Description of Exhibit ------ ---------------------- 99.1 Press Release, dated November 16, 2001. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 16, 2001 NEUROCRINE BIOSCIENCES, Inc. By: /s/ PAUL W. HAWRAN -------------------------- Paul W. Hawran Senior Vice President and Chief Financial Officer